Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Treatment of MDR-TB using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.

Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Aug 22. pii: 1900580. doi: 10.1183/13993003.00580-2019. [Epub ahead of print] No abstract available.

PMID:
31439686
2.

Impact of radiographic screening of more than 34 000 asylum seeker children.

Wolters BA, Akkerman OW, Aartsma Y, de Lange WCM, Schölvinck EH, van der Werf TS, van Hest R.

Eur Respir J. 2019 May 20. pii: 1900579. doi: 10.1183/13993003.00579-2019. [Epub ahead of print] No abstract available.

PMID:
31109988
3.

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep. No abstract available.

PMID:
31048350
4.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
5.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

6.

[Tuberculosis: from compulsory admission to compulsory treatment].

Drijver-Messelink MT, Kerstjens HAM, de Lange WCM, de Vries J, van der Werf TS, Akkerman OW.

Ned Tijdschr Geneeskd. 2018 Aug 3;162. pii: D2439. Dutch.

PMID:
30182637
7.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

8.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

9.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

10.

Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.

Ravensbergen SJ, Louka C, Lokate M, Bathoorn E, Pournaras S, van der Werf TS, de Lange WCM, Stienstra Y, Akkerman OW.

Am J Trop Med Hyg. 2018 Feb;98(2):376-378. doi: 10.4269/ajtmh.17-0544. Epub 2017 Dec 21.

11.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
12.

Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.

Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, van der Werf TS, Akkerman OW.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601724. doi: 10.1183/13993003.01724-2016. Print 2017 Mar. No abstract available.

13.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

14.

Neurological and functional recovery in tuberculosis patients with spinal cord injury in The Netherlands.

Wouda EMN, Stienstra Y, van der Werf TS, Kerstjens H, de Lange WCM, Coppes M, Kuijlen J, Tepper M, Akkerman OW.

NeuroRehabilitation. 2017;40(3):439-445. doi: 10.3233/NRE-161431.

PMID:
28222564
15.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

16.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

17.

Positive predictive value of ELISpot in BAL and pleural fluid from patients with suspected pulmonary tuberculosis.

Hofland RW, Thijsen SF, van Lindert AS, de Lange WC, van Gorkom T, van der Tweel I, Lammers JJ, Bossink AW.

Infect Dis (Lond). 2017 May;49(5):347-355. doi: 10.1080/23744235.2016.1269190. Epub 2016 Dec 26.

PMID:
28024452
18.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
19.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

20.

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Sturkenboom MG, Akkerman OW, van Altena R, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1237-1239. doi: 10.1183/13993003.00986-2016. Epub 2016 Aug 4. No abstract available.

21.

Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Wilffert B, Touw DJ, Alffenaar JW.

J Antimicrob Chemother. 2016 Oct;71(10):2691-703. doi: 10.1093/jac/dkw164. Epub 2016 May 26. Review.

PMID:
27231277
22.

High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015.

Ravensbergen SJ, Lokate M, Cornish D, Kloeze E, Ott A, Friedrich AW, van Hest R, Akkerman OW, de Lange WC, van der Werf TS, Bathoorn E, Stienstra Y.

PLoS One. 2016 May 4;11(5):e0154791. doi: 10.1371/journal.pone.0154791. eCollection 2016.

23.

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Alsaad N, Dijkstra JA, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3942-7. doi: 10.1128/AAC.02175-15. Print 2016 Jul.

24.

Implementing tuberculosis entry screening for asylum seekers: the Groningen experience.

Akkerman OW, de Lange WC, Schölvinck EH, Wolters B, Aartsma Y, van der Werf TS, van Hest R.

Eur Respir J. 2016 Jul;48(1):261-4. doi: 10.1183/13993003.00112-2016. Epub 2016 Mar 23. No abstract available.

25.

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17. No abstract available.

26.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

27.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
28.

Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.

van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1229-34. doi: 10.1183/13993003.01654-2015. Epub 2016 Jan 7.

29.

Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.

Akkerman OW, Odish OF, Bolhuis MS, de Lange WC, Kremer HP, Luijckx GJ, van der Werf TS, Alffenaar JW.

Clin Infect Dis. 2016 Feb 15;62(4):523-4. doi: 10.1093/cid/civ921. Epub 2015 Nov 3. No abstract available.

PMID:
26534926
30.

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.

Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.

Int J Antimicrob Agents. 2015 Sep;46(3):332-7. doi: 10.1016/j.ijantimicag.2015.06.008. Epub 2015 Jul 15.

PMID:
26228464
31.

[A sore throat: tumour, tuberculosis or both?].

van der Sar-van der Brugge S, Akkerman OW, van der Laan BF, de Lange WC, van der Werf TS.

Ned Tijdschr Geneeskd. 2015;159:A8942. Review. Dutch.

PMID:
26104006
32.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

33.

Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.

van der Paardt AF, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2015 Aug;46(2):444-55. doi: 10.1183/09031936.00147014. Epub 2015 May 28. Review.

34.

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.

van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS.

Int J Tuberc Lung Dis. 2015 Apr;19(4):406-12. doi: 10.5588/ijtld.14.0838.

PMID:
25859995
35.

The Never Ending Struggle Against Development of Drug Resistance.

Daskapan A, Stienstra Y, Akkerman OW, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Clin Infect Dis. 2015 Jul 1;61(1):137-8. doi: 10.1093/cid/civ238. Epub 2015 Mar 25. No abstract available.

PMID:
25810289
36.

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Sturkenboom MG, Akkerman OW, Bolhuis MS, de Lange WC, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Apr;59(4):2474. doi: 10.1128/AAC.05173-14. No abstract available.

37.

The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.

Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, Alffenaar JW.

Eur Respir J. 2015 Feb;45(2):569-71. doi: 10.1183/09031936.00142614. No abstract available.

38.

Breakpoints and drug exposure are inevitably closely linked.

Alffenaar JW, Akkerman OW, Bolhuis MS, Boeree MJ, de Lange WC, van der Werf TS.

Antimicrob Agents Chemother. 2015 Feb;59(2):1384. doi: 10.1128/AAC.04485-14. No abstract available.

39.

Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.

Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2014 Mar;43(3):884-97. doi: 10.1183/09031936.00113713. Epub 2013 Aug 29. Review.

40.

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2013 Aug;57(8):3676-80. doi: 10.1128/AAC.00558-13. Epub 2013 May 20.

41.

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.

Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Dec;42(6):1614-21. doi: 10.1183/09031936.00001913. Epub 2013 Mar 21.

42.

Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment.

Santbergen B, Vriens PH, de Lange WC, Van Kasteren ME.

BMJ Case Rep. 2013 Jan 25;2013. pii: bcr2012008161. doi: 10.1136/bcr-2012-008161.

43.

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.

Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Aug;42(2):504-12. doi: 10.1183/09031936.00114812. Epub 2012 Oct 25.

44.

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS Med. 2012;9(8):e1001300. Epub 2012 Aug 28.

45.

Hypersensitivity pneumonitis caused by Mycobacterium avium subsp. hominissuis in a hot tub, as proven by IS1245 RFLP and rep-PCR typing.

van der Zanden RJ, Magis-Escurra C, de Lange WC, Hoefsloot W, Boeree MJ, van Ingen J, van Soolingen D.

Int J Mycobacteriol. 2012 Sep;1(3):152-4. doi: 10.1016/j.ijmyco.2012.07.006. Epub 2012 Aug 24.

46.

Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5758-63. doi: 10.1128/AAC.01054-12. Epub 2012 Aug 27.

47.

XDR tuberculosis.

van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D.

Lancet Infect Dis. 2011 Aug;11(8):585. doi: 10.1016/S1473-3099(11)70200-6. No abstract available.

PMID:
21798459
48.

[Nontuberculous mycobacteria: clinically relevant].

van Ingen J, Hoefsloot W, de Lange WC, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Ned Tijdschr Geneeskd. 2010;154:A1178. Review. Dutch.

PMID:
20482903
49.

Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time.

van Ingen J, Verhagen AF, Dekhuijzen PN, van Soolingen D, Magis-Escurra C, Boeree MJ, de Lange WC.

Int J Tuberc Lung Dis. 2010 Jan;14(1):99-105.

PMID:
20003702
50.

Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.

Hoefsloot W, van Ingen J, de Lange WC, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Eur Respir J. 2009 Oct;34(4):926-31. doi: 10.1183/09031936.00039009. Epub 2009 Apr 22.

Supplemental Content

Loading ...
Support Center